Streetbeat News

Stock Prices

COIN

MARA

RIOT

Shares of crypto-related companies COIN, MARA, and RIOT are trading lower due to a decline in Bitcoin prices.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:53 pm

CRSP

RBC Capital analyst Luca Issi has maintained a 'Sector Perform' rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $50 to $57.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:41 pm

ATUS

Altice USA is negotiating the sale of Cheddar News to Regent LP, a private equity firm. The deal may involve an earn-out structure, with no initial payment but potential future proceeds for Altice based on Cheddar's performance, possibly reaching $50 million. Altice USA, facing a nearly 60% stock price drop and broadband losses, previously acquired Cheddar for $200 million in 2019. Regent has a history of media sector investments. No final deal is confirmed, and Altice USA declined to comment on the ongoing private discussions.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:40 pm

KROS

Keros Therapeutics' stock price has declined following the presentation of clinical data from its KER-050 program at the 65th ASH Annual Meeting and Exposition.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:39 pm

TLS

Northland Capital Markets analyst Nehal Chokshi has maintained an Outperform rating on Telos Corporation (NASDAQ:TLS) and increased the price target from $4 to $6.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:38 pm

BPMC

Blueprint Medicines' stock is trading higher following the company's announcement of new data that emphasizes its dedication to improving the scientific knowledge and treatment options for systemic mastocytosis.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:38 pm

COGT

Cogent Biosciences Inc (NASDAQ:COGT) reported positive results from its Phase 2 APEX trial for bezuclastinib in treating advanced systemic mastocytosis (AdvSM), with a strong safety profile and high overall response rates. Despite these positive clinical updates, COGT shares fell by 51.03% to $4.23. The company continues to enroll for Part 2 of the APEX trial and the SUMMIT Phase 2 trial for nonadvanced systemic mastocytosis (NonAdvSM), with completion expected by the end of 2024.

Portfolio Pulse from Vandana Singh

December 11, 2023 | 4:37 pm

EW

Truist Securities analyst Richard Newitter has reaffirmed a Buy rating on Edwards Lifesciences (NYSE:EW) and increased the price target from $76 to $78.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:36 pm

CVS

TD Cowen analyst Charles Ryhee has maintained an Outperform rating on CVS Health (NYSE:CVS) but has reduced the price target from $102 to $99.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:32 pm

MOR

MorphoSys shares are up following positive results from the Phase 3 MANIFEST-2 study of pelabresib with ruxolitinib in myelofibrosis patients.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:32 pm